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The HIV and AIDS epidemic is a major catastrophe that affects millions of people 
worldwide. Antiretroviral medication combinations have revolutionised HIV 
treatment since 1996, transforming the virus from a death sentence to a manageable 
condition. In order to obtain full therapeutic benefits it is vitally important that 
patients adhere to their prescribed medication. Being informed about the disease and 
medication contributes to patient adherence and management. 
Pharmacists are considered to be the most accessible health professional and can help 
HIV -infected patients deal with barriers to medication access, manage adverse effects 
and medication interactions, and adhere to medication regimens by appropriate 
counselling. The public sector is defined as that part of an economy that is controlled 
by the state. At the study site, which is a public sector facility, the roll out of 
antiretroviral medication started in 2006. At the time all patients were counselled by 
trained counsellors, before seeing a doctor. At the pharmacy the medication was 
collected with no intense counselling by a pharmacist as the patients would have 
visited the trained counsellors first. 
Subsequently it was found that there were many queries regarding HIV and AIDS. It 
was then decided in October 2007, that the pharmacist support the counselling done 
by the counsellors in that they should reinforce what was said by the counsellors, 
together with giving detailed information to patients on their health and medication. 
This study was therefore undertaken to measure pharmacists' role in the 
management and adherence ofHIV infected patients at this institutional facility. 
Method: 
The study was undertaken at a public sector health facility using anonymous 
structured questionnaires and was divided into 3 phases: Pre-Intervention, 
Intervention and Post-Intervention phases. After obtaining patient consent the 
questionnaires were administered during the I st phase. A month later all patients 
visiting the pharmacy were counselled intensely on various aspects of HIV and the 
antiretroviral medication. Thereafter patients who took part in phase 1 were asked to 
participate in the 2nd phase. After obtaining their consent again, the same 
questionnaire was administered to them. Quantitative variables were compared 
between pre and post intervention using paired t-tests or Wilcoxon signed ranks tests. 
Categorical variables were compared using McNemar's chi square test (Binary) or 
McNemar-Bowker test for ordinal variables. 
Results: 
A response rate of87.5% was obtained with the majority of the patients being female. 
Almost 70% of the participants were in the age-range of 21-40 years old. The majority 
of the participants did not have post school education. 
Most of the participants (95.4%) did not know that HIV is a virus that causes AIDS in 
the pre intervention phase, but this decreased to 93.7% in the post intervention phase. 
The participants knowledge of people who have sexually transmitted diseases are least 
at risk of getting HIV, healthy food will cure HIV and smoking and drinking alcohol 
will weaken the mv virus, increased significantly from the pre-intervention phase to 
the post intervention phase. Knowledge on the modes of transmission either increased 
or remained unchanged. 
Overall the mean knowledge score on the disease itself had increased significantly 
(SD 6.6%) [p<O.O 1] after the pharmacists' intervention (pre-intervention was 82.1 %, 
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post-intervention was 86.3%). In both phases, over 40% of all patients stored their 
medication in the cupboard. The majority of the patients took their medication either 
with or without food at both phases of the study. After the intervention, the frequency 
of taking medication with a fatty meal or any time they remember was decreased to O. 
A significant improvement was noted in the overall knowledge score with regards to 
medication taking and storage (p<0.05). 
Conclusion: 
Pharmacist intervention had a positive impact on HIV infected patients' HIV and 




Public sector is defined as that part of an economy that is controlled by the state. The 
human immunodeficiency virus (HIV) is a retrovirus that causes the acquired immune 
deficiency syndrome (AIDS). It is transmitted in body fluids, in which there is a 
severe loss of cellular immunity, leaving the sufferer susceptible to infection and 
I· I rna 19nancy. 
The World Health Organisation (WHO) has defined health as the state of complete 
physical, mental and social well being and not merely the absence of disease or 
infirmity.2 
Pharmacists are often considered the most accessible health professional.3 A 
pharmacist can help HlV -infected patients deal with barriers to medication access, 
manage adverse effects and medication interactions, and adhere to medication 
regimens
3 
by appropriate counselling. A patients' ability to adhere to antiretroviral 
regimens is essential to achieving the goals of drug therapy. 3 
It has been estimated that >95% of all highly active antiretroviral therapy (HAART) 
doses must be taken to maintain durable suppression of HI V in >80% ofpatients.4 
In order to ensure long-term viral suppression, the strict and sustained adherence to all 
prescribed antiretroviral medication is essentiaLS The development of resistance to 
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antiretroviral medication is a major impediment to optimum treatment of HIV 
infection.6 The development of viral resistance and an increase in viral replication 
results from the intermittent exposure of the virus to the drugs.5 This is then followed 
by the deterioration ofthe immune system. 5 
Failure to take all prescribed doses of antiretroviral medication, may result in 
inadequate drug concentrations, which can result in incomplete inhibition of HIV 
replication and may accelerate viral resistance to antiretroviral therapy.7 
Antiretroviral therapy can fail because of poor adherence, acquired drug resistance, 
poor drug absorption, drug-drug interactions or lack of drug potency. 8 
If the individual drugs of an antiretroviral regimen are not taken correctly or omitted, 
there is a risk of resistant HIV strains developing. These resistant strains can be 
transmitted to other people.9 
Like many other chronic illnesses, HIV infection affects nearly every organ system of 
the body. HIV is pathogenic in some instances, and super-infection by bacteria, other 
viruses, or fungi is common in the advanced stages ofHIV infection.3 Among those at 
high risk for HIV infection are intravenous drug users and the severely mentally ill, 
whose conditions may discourage testing for HIV infection or disclosure of HIV 
status can also hinder treatment.3 In housing and employment, discrimination against 
HIV -infected individuals persists and can impede the delivery of health care by 
disrupting the stability of home and work Iife.3 
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The HAART (highly active antiretroviral therapy) regimens comprise at least three 
drugs and require that many medication be taken each day.4 There are many reasons 
for patients being non-adherent to antiretroviral medication, but the most frequently 
cited one is that they forget; other reasons include being away from home; being busy 
or experiencing a change in daily routine. lo Regimen complexity is composed of a 
number of regimen attributes, including the number of pills; pill size; frequency and 
timing of doses; dietary and/or water requirements or restrictions; the number of 
adverse events (AE's); medication storage requirements; number of prescriptions; as 
well as the influence of other factors on a patients' Iifestyle.3 
Efforts should be made to educate and motivate patients, simplify treatment regimens 
and tailor them to individual lifestyles, prepare for and manage side effects, and 
address the concrete issues that may be a barrier to adherencelo and positive patient 
disease management. 
HIV is a disease stigmatised by many. Patients do not always feel comfortable to ask 
the pharmacist or other health care professionals about the disease due to its stigma. 
One study revealed the extent to which people are stigmatised and discriminated 
against by health care systems. The study also revealed withholding of treatment, non-
adherence of hospital staff to patients, HIV testing without consent, lack of 
confidentiality and denial of hospital facilities and medicines. Ignorance and lack of 
knowledge about HIV transmission also fuel such responses. I I 
Other reasons for poor adherence to antiretroviral therapy have been identified. These 
include poor clinician-patient relationship, drug and alcohol abuse, mental illness, 
lack of patient education and inability of patients to identify their medications, and the 
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lack of reliable access to primary medical care. Other factors that may influence poor 
adherence include domestic violence, discrimination, medication side-effects and 
homelessness. 12,I3 
Pharmacists involved in the care of HIV -infected patients participate with other 
members of the health care team in the management of patients, for whom medication 
is a focus of therapy.3 The pharmacists responsibility is to optimize the patients 
medication therapy.3 Particular care is needed in the prescribing and dispensing 
phases because the names of many antiretroviral agents sound and look similar.3 
Verification of the antiretroviral regimen and their dosages is important because 
dosing recommendations change frequently as more becomes known about individual 
drug pharmacokinetics and because drug-drug interactions may be used clinically to 
simplify or increase the efficacy of drug regimens.3 A number of antiretroviral 
medication cannot be taken with certain foods, and it is the responsibility of the 
pharmacist to ensure that the patient and caregivers are aware of these dietary 
restrictions.3 
Seeing that 95% of all people diagnosed with HIV reside in developing countries, it is 
evident that the role of the pharmacist is one of the keys in the monitoring of 
compliance in HIV and AIDS infected patients. Since HIV and AIDS is a lifelong 
disease, the pharmacist must make a long term investment of time and commitment to 
infected patients, and must obtain and impart knowledge about the evolving 
treatments for the disease. 14 
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The antiretroviral (ARV) clinic at the study site was in operation since October 2006. 
Prior to the study being conducted, all patients were counselled by trained counsellors 
on three consecutive visits to the ARV clinic, before being seen by a doctor for the 
first time and then going to the ARV pharmacy where pharmacists would hand over 
the medication, only explaining to patients when and how often to take the 
medication. No intense counselling on the ARV medication was done. 
However there appeared to be many queries by patients regarding their health, 
medication, side effects, disease knowledge, and medication storage. Thereafter it was 
decided that the pharmacist support the counselling done by the counsellors in that 
they should reinforce what was said by counsellors, together with giving detailed 
information to patients on their health and medication. 
In October 2007, pharmacists were expected to dispense and counsel on ARV 
medication as part of their management of HIV infected patients. This study was 
therefore undertaken to measure pharmacists' role in the management and 
adherence ofHIV infected patients at this institutional facility. 
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With this aim in mind the following were the objectives of the study. 
At baseline: 
• To obtain the demographic profile of patients, 
• to obtain patients current knowledge of HIV and AIDS 
• to ascertain patients understanding of medication and side effects 
• to assess practices with regard to medication use and adherence 
• to determine perceptions about management. 
After a month: 
• to assess changes in all of the above objectives after comprehensive 
counselling on medication taking, disease condition, together with information 
on storage, side effects experienced and the importance of adherence. 
• To disseminate findings and make recommendations to the relevant authorities 
9 
BACKGROUND 
The initial introduction of the Acquired Immune Deficiency Syndrome (AIDS) in 
1981 saw this new disease complex become a major global public health problem. ls 
1.1 Epidemiology 
HIV remains a global health problem of unprecedented dimensions. Unknown 27 
years ago, HIV has already caused an estimated 25 million deaths worldwide and has 
generated profound demographic changes in the most heavily affected countries. 16 
In the countries most heavily affected, HIV has reduced life expectancy by more than 
20 years, slowed economic growth, and deepened household poverty. 16 
In South Africa in 2008, an estimated 5.2 million people were living with HIV and 
AIDS. Almost one-in-three women aged 25-29, and over a quarter of men aged 30-34 
are living with HIV. Among those aged two and older, HIV prevalence varies by 
province with the Western Cape (3.8%) and Northern Cape (5.9%) being least 
affected, and Mpumulanga (15.4%) and KwaZulu-Natal (15.8%) at the upper end of 
the scale. 17 
The natural age distribution in many national populations in sub-Saharan Africa has 
been dramatically skewed by HIV.16 
Sub-Saharan Africa remains the region most heavily affected by HIV, accounting for 
67% of all people living with HIV and for 75% of AIDS deaths in 2007. 16 
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The cause of the Acquired Immune Deficiency Syndrome (AIDS) has been shown to 
be a retrovirus. It is known as the Human Immunodeficiency Virus type 1 or HIV -1 . 
Infection with this virus has become a pandemic and is a major cause of mortality in 
sub-Saharan Africa and other developing countries, whilst infection with HIV -2 is 
restricted to West Africa. 18 
1.2 Structure of the Human Immunodefiency Virus [HIYl 
The virus has an outer envelop, its genetic message carried within a capsid as 
ribonucleic acid (RNA) that also encloses a reverse transcriptase enzyme to reverse 
transcribe its RNA to pro-viral deoxyribonucleic acid (DNA) in host cells.8 
The virus is approximately 80-100nm in diameter. The surface of the virus is made up 
of 72 knobs or peplomers (glycoprotein structures-gp 120) placed on the viral 
envelope.19 
The envelope glycoproteins are heavily glycosylated, and carry receptor sites for the 
CD4 lympocytes that are important for viral infectivity.20 
The inner surface of the envelope is lined with the matrix protein p 17 which is needed 
for viral structure. The virus contains a cylindrical or cone shaped core (p24 antigen) 
or nucleocapsid. The core contains the genome as well as the three viral enzymes 
reverse transcriptase (RT), integrase and protease.19 
The proviral DNA of retroviruses in infected cells has three major genes: encoding 
structural proteins for nucleocapsid (gag), reverse transcriptase and other essential 
enzymes (pol) and the envelope antigen (env) which encodes the envelope 
glycoproteins. Theses genes give HIV -1 its expression, infectivity and replication 
control. 20,21 
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1.3 The pharmacist and healthcare 
The pharmacist is an integral part in the dispensing process where dispensing is 
defined in terms of the Pharmacy Act as being the " interpretation and evaluation of a 
prescription, the selection, manipulation or compounding of the medicine, the 
labelling and supply of the medicine in an appropriate container according to the 
Medicines Act and the provision of information and instructions by a pharmacist to 
ensure the safe and effective use of medicine by the patient,,22 
The information given must be structured to meet the needs of individual patients and 
the pharmacist must ensure that any information or services offered by a pharmacy to 
patients in the area of health promotion are safe, up-to-date and in accordance with the 
relevant local and national guidelines. Further more the information provided to 
patients regarding their medication use must always be done with professional 
judgement and the prescriber should be contacted when necessary. The pharmacist, as 
per the Act, is obliged to monitor patient outcomes by assessing the patient for signs 
of compliance, effectiveness and safety of the therapy.23 Finally, the pharmacist 
should identify areas for modification, implementation of modifications (taking into 
account legal requirements), revise the patient record and record the action taken.23 
1.4 Role of the Pharmacist in mv and AIDS 
As the management of mv and AIDS patients often involves complicated medication 
therapy, pharmacists have been found to be the most appropriate persons to monitor 
and advise on this important aspect of care with one of the main areas of involvement 
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being the provision of advice and information on new medication, drug interactions, 
adverse drug reactions and establishment and maintenance of an AIDS data base.24 
The pharmacist can also act as a resource for information on HIV and AIDS to help 
dispel myths and misinformation about the disease and they can be a provider of 
testing services and counselling as well as preventative methods and information.25 
1.5 HIV in South Africa 
There were approximately 5.7 million people living with HIV in South Africa, and 
almost one thousand AIDS deaths occurring every day by the end of 2005.26 It is 
believed that almost half of all deaths, and over 70% of deaths among those aged 
between 15 and 49 in South Africa, are caused by AIDS, with over half of fifteen year 
olds not expected to reach the age of sixty.27 Caring for HIV and AIDS patients is 
placing a huge burden on the hospitals with estimates that HIV -positive patients 
would soon account for 60%-70% of medical expenditure in South African 
hospitals.
28 
In 2006, 21 % of teachers in South Africa were living with HIV thus 
having a major impact on the education sector as wel1.29 
The South African Governments' response to the HIV and AIDS epidemic is found in 
the HIV/AIDS and STI Strategic Plan for South Africa 2007-2011. The plan purposed 
to provide a broad national framework around four areas: prevention and treatment; 
care and support; research, monitoring and evaluation; human and legal rights.3o 
In 2003 the South African government made a decision to provide antiretroviral 
(ARV) therapy in the public sector as part of the Operational Plan for the 
comprehensive HIV and AIDS care, Management and Treatment for South Africa. 
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The key to the success of this programme depended on patients adhering to their 
d· . 31 me lcatlOn. 
The public sector roll-out programme for the prevention of mother-to-child 
transmission with nevirapine started at 18 pilot sites in 2000. An antiretroviral CARY) 
treatment plan was published in 2003 and the roll-out of treatment started at 32 
accredited sites in April 2004, aiming to treat all South Africans needing antiretroviral 
therapy. 17 
1.6 Social factors and myths associated with HIV and AIDS 
Many people delay or refuse testing due to stigma and denial related to suspected 
infection. Diagnosis is often followed by fear and despair due to the poor quality of 
counselling and lack of support. Poverty prevents many infected people from 
maintaining adequate nutrition to help prevent the onset of illness. The limited access 
to clinics, long waiting lists for antiretroviral treatment programmes mean that many 
people become seriously ill before accessing treatment. In South Africa on average 
there are three women infected with HIV for every two men that are infected. Women 
therefore face a greater risk of HI V infection.31 
Many myths about HIV and AIDS have contributed to prejudice and stigma about the 
disease. One myth is that HIV only affects gay men. The reality of this is that HIV can 
affect anyone. Behaviours such as unsafe sex and multiple sexual partners can put a 
person at risk for HIV infection. Another myth is that HIV can be cured by sex with a 
virgin and that new drugs can cure AIDS. The reality here is that there is no cure for 
HIV infection. The amount of virus in the body and symptoms of HIV can be 
managed by highly active antiretroviral therapy.4 Sex with a virgin only exposes the 
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virgin to mv and does not cure HIV. Some people believe that mv and AIDS can be 
spread by mosquitoes not knowing that when a mosquito bites, it injects its own saliva 
into the person it is biting and not injecting blood from the last person it bit.32 
1.7 Antiretroviral therapy 
Advances in the treatment of HIV in the past several years have resulted in the HIV 
epidemic being looked at differently.33 An increasing number of cases of HIV 
infection and rising mortality have intensified a search for an antiviral agent that 
effectively treats those already infected and a vaccine that is effective in preventing 
infection. At present antiretroviral therapy is capable of increasing, to some extent, the 
life expectancy of patients with symptomatic disease but according to current 
evidence it does not result in significant long-term benefit when given as mono 
therapy in asymptomatic infection.34 
The best way to achieve maximum viral suppression is by highly active antiretroviral 
therapy (HAART) which consists of combinations of at least three antiretrovirals.35 
A major impediment to the optimum treatment of HIV infection is the development of 
resistance to antiretroviral drugs.36 
The primary goals of antiretroviral therapy is to decrease HIV related morbidity and 
mortality i.e. the patient should experience fewer HIV related illnesses, their CD4 
count should rise and remain above the baseline count, the patients viral load should 
become undetectable «400 copies/ml) and remain undetectable on antiretroviral 
therapy.37 
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The secondary goal is to decrease the incidence of HIV through the increased uptake 
of voluntary counselling and testing with more people knowing their status and 
practising safer sex, reduction of transmission in discordant couples and by reducing 
the risks ofHIV transmission from mother to child.37 
When initiating therapy it is recommended that it be guided by the monitoring of 
laboratory parameters such as the plasma HIV RNA and the CD4 T cell count. 
Different types of assays are used to detect viral load e.g. the polymerase chain 
reaction (PCR) test, the branched chain DNA (bDNA) test and the nucleic acid 
sequence-based amplification (NSBA) test.38 
There are 4 classes of antiretroviral drugs, based on their mechanism of action39 
Reverse Transcriptase Inhibitors: 
These drugs inhibit the viral enzyme reverse transcriptase, (that copies viral RNA into 
DNA in the newly infected cell) in order to prevent HIV from replicating. 
Nucleoside Reverse Transcriptase Inhibitors (NRTI) / Nucleotide Reverse 
Transcriptase Inhibitors (NtRTI): 
NRTIINtRTI function by inhibiting the synthesis of DNA by reverse transcriptase 
(RT). The RT enzyme cannot distinguish phosphorylated NRTI from their natural 
counterparts and therefore attempt to incorporate both forms in the synthesis of viral 
DNA. 
Non Nucleoside Reverse Transcriptase Inhibitors (NNRTI): 
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These drugs bind directly to the reverse transcriptase enzyme, thereby altering its 
structure, so that it is unable to function properly. 
Protease Inhibitors (PI): 
Protease a viral enzyme breaks up the proteins made by mRNA. By binding to the 
active site of the viral protease enzyme, PIs prevent the processing of viral proteins 
into functional forms. Viral particles are still produced when the protease is inhibited, 
but these particles are unable to infect new cells. 
Entry and Fusion inhibitors: 
These drugs inhibit HIV from entering a host cell by preventing the binding of gp41 
to the chemokine receptor. With no attachment, HIV cannot insert viral RNA into the 
cell, and is thus unable to replicate.40,41 
Integrase Inhibitors: 
These drugs interfere with HIV's integrase enzyme, which is required for viral 
replication.40,41 
Combination Therapy: 
Combination therapy is associated with improved health outcomes for people living 
with HIV and AIDS. Antiretroviral drugs must always be combined in order to delay 
or prevent the emergence of HIV resistance. Mono therapy e.g. zidovudine should 
only be used in vertical transmission prophylaxis. A number of different combinations 
have been shown to be effective in reducing the number of opportunistic infections 
and other HIV related conditions and delaying the onset of AIDS.9 
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Recommended regimens42 during the study 
First line regimens for adults: 
[Stavudine 30mg or 40mg lLamivudine 150mg] twice daily 
+ 
[Efavirenz 600mg or 400mg if < 40 kg] at night 
Or 
[nevirapine 200mg] daily for the first two weeks and then increasing to twice daily in 
next two weeks 
Regimen 2 includes: 
Zidovudine with didanosine and lopinavir/ritonavir 
1.8 Antiretroviral adverse effects 
Antiretroviral therapy can have a wide range of adverse effects on the human body. 
Common but mild adverse effects occurring early in most antiretroviral regimens 
include gastrointestinal effects such as bloating, nausea and diarrhoea, which may be 
transient or may persist throughout therapy.43 
Other common adverse effects are fatigue and headache caused by Zidovudine and 
nightmares associated with Efavirenz. Other uncommon but more serious adverse 
effects associated with antiretroviral therapy, includes Zidovudine-associated 
anaemia, Stavudine-associated peripheral neuropathy, Protease inhibitor-associated 
retinoid toxicity and Non-nucleoside reverse transcriptase inhibitor-associated 
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hypersensitivity reactions. These are treated according to accepted therapy for these 
conditions in patients not receiving HAART. Other adverse effects include lactic 
acidosis, hepatic steatosis, hyperlactatemia, hepatotoxicity, hyperglycaemia, fat 
maldistribution, hyperlipidemia, bleeding disorders, osteoporosis and skin rash. Some 
of the adverse effects mentioned will be explained below. 
Skin rash 
Rash is a common adverse effect of the NNRTI's, particularly nevirapine. 
Approximately 16% of patients taking this agent experience a mild to moderate 
maculopapular rash, with or without pruritis, on the trunk, face and extremities, within 
the first 6 weeks on therapy.44 
Although most rashes are self-limited, nevirapine should be permanently discontinued 
if the rash is severe.45 Severe rashes occur in about 6.5% of nevirapine-treated 
patients, mainly during the first 4 weeks of treatment, including Stevens-Johnson 
syndrome and toxic epidermal necrolysis in less than 1 % of all patients treated with 
nevirapine.44 
Lactic acidosis, hepatic steatosis and hyperlactatemia 
NRTI's are nucleoside analogues that prevent DNA elongation and viral 
reproduction. These drugs are triphosphorylated intracellularly to become 
nucleotides and are then incorporated into the viral DNA chain by the viral 
reverse transcription enzyme. Their presence in the DNA halts transcription. 
Lactic acidosis has been associated with Zidovudine, Didanosine and Stavudine 
th 46,47,48 Th I" I . ft h . erapy. e c mIca course IS 0 en c aractenzed by vague complaints of 
malaise, nausea and vomiting, fatigue and tacypnea, followed by liver failure, 
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cardiac dysrhythmias and death.49 
In addition to this serious but rare syndrome, there is evidence of a persistent mild 
to moderate elevation of venous lactic acid (hyperlactatemia) in 10%-20% of 
patients undergoing long term treatment with NRTI containing regimens. The 
hyperlactatemia and associated symptoms tend to resolve when NRTI's are 
d· . d 50 Iscontmue . 
NRTI-associated lactic acidosis occurs when during normal glycolysis, glucose is 
converted to pyruvate, which is then transferred into the mitochondria. There, most of 
the pyruvate is converted into acetylcoenzyme A, which in turn enters the 
tricarboxylic acid cycle to form NADH (the reduced form of nicotinamide adenine 
dinucleotide). The mitochondria uses the NADH to produce adenosine triphosphate 
through oxidative phosphorylation. DNA polymerase is inhibited in the presence of 
NRTI's, which diminishes mitochondrial function, especially oxidative 
phosphorylation. This allows pyruvate and NADH to accumulate, enhancing the 
conversion of pyruvate to lactate. Impaired oxidation may also lead to a decrease in 
fatty acid oxidation. Free fatty acids then accumulate and are metabolized to 
triglycerides. These excess triglycerides may accumulate in the liver, causing the 




Transaminitis and hepatotoxicity are associated with most of the antiretroviral agents. 
Protease inhibitors are the drug class most focused on. The hypersensitivity reaction 
observed with nevirapine can also include severe transaminitis. NRTI's are also 
associated with the risk of mitochondrial toxicity and hepatic steatosis. so 
Fat ma/distribution 
Lipodystrophy is part of a metabolic syndrome that includes dyslipidemias, insulin 
resistance and accelerated bone loss. The main clinical features are peripheral fat loss 
(lipoatrophy) in the face, limbs and buttocks, accompanied by central fat 
accumulation in the abdomen and breasts and over the dorsocervical spine (the 
'buffalo hump') and lipomas. PI therapy has been most strongly linked to 
lipodystrophy syndrome, although NRTI's, especially stavudine have also been 
associated with lipodystrophy.sO 
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1.9 Antiretrovirals and food restrictions: 
The table below represents antiretrovirals and their food restrictions
51 
Nucleoside reverse transcriptase inhibitors (NRTI) 
Generic Name Food Restriction 
Didanosine (ddl) Take on empty stomach one hour before or two 
hours after food. 
Give 1 hr before or 2 hr after tenofovir. If 
tenofovir is taken together with didanosine, the 
dose of didanosine should be lowered. 
Zidovudine (AZT) No food restrictions 
Lamivudine (3TC) No food restrictions 
Stavudine (d4T) No food restrictions 
Zalcitabine( ddC) Do not take with antacids 
Zidovudine+Lamivudine No food restrictions 
Abacavir May be taken with or without food 
Abacavir+Lamivudine+ Zidovudine May be taken with or without food 
Nucleotide reverse transcriptase inhibitors (NRTI) 
Generic Name Food Restriction 
Tenofovir Absorption is enhanced by food. Give 2hr or Ihr 
after didanosine. If tenofovir is taken together 
with didanosine, the dose of didanosine should be 
lowered 
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Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
Generic Name Food Restriction 
Efavirenz No food restrictions. A high fat meal may 
increase absorption and should be avoided 
Nevirapine No food restrictions 
Delavirdine Can be taken with food 
Protease inhibitors (PI) 
Generic Name Food Restriction 
Indinavir Take with lots of fluid on an empty stomach or 
with a low-fat snack 
Nelfinavir Take with a meal or light snack 
Ritonavir Take with a full meal. Take 2 hrs apart from 
didanosine 
Saquinavir soft and hard gel capsules Take within 2 hrs of a high fat meal. Grapefruit 
juice increases saquinavir concentration 
Amprenavir Ingestion of a high fat meal may decrease 
absorption. Take antacids or didanosine at least 
I hr before or after amprenavir 
Lopinavir/ritonavir Take 2 hrs before or Ihr after didanosine. Take 
with food to enhance absorption. 14 
Some drugs cannot be given concomitantly; many drugs alter the concentration of 
others, resulting in toxic and sub-therapeutic levels, thereby demanding a change in 
dosage of one or more medication. Some oral medication should be given with food 
and some medication should not be co-administered with other medication whilst 
some other medication will cause therapeutic failure. 52 Nausea and vomiting caused 
by antiretroviral medication may cause adherence to suffer and should be therefore 
23 
managed accordingly. Anti-emetics taken half an hour before the antiretroviral dose 
up to 3 times daily may be helpful.37 
Therefore it becomes important for the proper counselling to be given to patients 
taking medication for their HIV and AIDS condition. 
1.10 HIV Counselling and Testing mCT) 
HIV counselling has both prevention and care as its objectives. It concentrates on 
emotional, behavioural, and social issues related to possible or actual infection with 
HIV. In essence, counselling is a confidential dialogue between a client (in 
counselling, the word "client" is preferred to "patient") and a counsellor, aimed at 
enabling the client to cope with stress and take personal decisions related to HIV and 
AIDS.53 
HIV counselling and testing (HCT) is a combination of two activities - counselling 
and testing - into a service that amplifies the benefits of both. It is an approach that is 
useful in all settings - resource-rich and resource-poor, urban and rural. 53 
HIV counselling and testing has a two-pronged approach. Firstly it helps to determine 
who requires care and treatment. This includes both antiretroviral therapy (ART) and 
interventions to prevent mother-to-child HIV transmission (PMTCT). Secondly it 
helps prevention and transmission of HI V infection to others.53 
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Additionally, HIV counselling and testing can also stimulate discussion about HIV 
and AIDS and in turn reduce stigma and discrimination.53 
HIV testing needs to be done with much care and consideration. Due to the 
implications of receiving a positive result a person must always be counselled before 
testing in order to prepare the person as far as possible for the impact of the results (a 
pre-test counselor interview). Careful counselling must be provided to a person after 
the test (a post-test counselor interview). Counselling must be provided to persons 
whose results are negative to ensure that their results remain negative. It is critical at 
the start to establish a trusting relationship with the patient. Total privacy must be 
assured during the consultation with the patient?3 
1.11 The study site 
The study site i.e. the ARV clinic was situated in a public sector hospital (community 
health centre) situated in the northern suburbs of the eThekwini Metro ofKwaZulu-
Natal. The pharmacy in this facility saw plus 1000 patients per day ranging from 
patients visiting the facility for acute ailments to chronic conditions. Medicines were 
dispensed accordingly. The ARV roll out at this clinic started in October 2006, with 
the pharmacist being funded by a Non Governmental Organisation. However in May 
2007, the management of the ARV pharmacy was taken over by pharmacists from the 
public sector institution. 
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1.12 The Province of KwaZulu-Natal 
This province remains the epi centre of the epidemic with a prevalence of38.7%54 
In South Africa there is considerable geographical variation in the distribution of HIV 
infection, being highest along the east coast and lowest in the west coast of South 
Africa.55 While the overall doubling time at the start of the epidemic in South Africa 
was 13.8 months, the doubling time at a provincial level varied from 9.2 months in the 
Northern province of South Africa to 14.1 months in KwaZulu-Natal. The province of 
KwaZulu-Natal has the largest population in South Africa with just over 10 million 
people, according to mid 2007 estimates by Statistics South Africa.56 Slightly more 
than 50% of South Africa's population live in urban areas, due to migration from rural 
to urban and also because much of the open space is dry and arid.56 
The eThekwini Metro in KwaZulu-Natal has a high urban concentration56 with a 
population of 3,090, 126, where 51.9% (1 605 080) are females whilst 48.1 % 




2.1 Study design and Site 
A descriptive cross sectional study was undertaken at the ARV clinic in a public 
sector institutional facility situated in the province of KwaZulu-Natal. This site was 
chosen because the researcher was based at this ARV clinic. The study was done in 
October and November 2007. The researcher had taken employment in January 2007 
at which time the medicines were handed over to the patients without much 
counselling. 
The study was divided into three phases: Pre-Intervention Phase (Phase 1), 
Intervention phase (Phase 2), and a Post-Intervention Phase (Phase 3). There was no 
control group as participants acted as their own controls in the pre-intervention phase. 
2.2 Sample Population 
During the study period, 400 patients were on the database of the ARV clinic. All of 
these patients were invited to participate in the study. Of these 200 patients gave 
consent to be part of the study. 
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2.3 Instruments 
An anonymous closed ended structured questionnaire was designed in both languages 
i.e. English (Appendix 1) and Zulu (Appendix 2). The questionnaire included sections 
on demographics, knowledge of medicines, medicine taking and disease conditions 
together with questions on storage, side effects experienced and adherence patterns. 
The questionnaire was pilot tested amongst the nurses at the ARV clinic and also 
amongst the pharmacists in the clinic before administration. The nurses and 
pharmacists amongst whom the questionnaire was pilot tested were then required to 
give input and any discrepancies or other ethical issues that was raised, was noted and 
corrected in the questionnaire. 
2.4 Pre-Intervention Phase (Phase 1) 
During the patients' clinic visit, the study was explained to each participant 
(Appendix 3) and a consent form was completed (Appendix 4). The questionnaire was 
then administered and assistance was given by the researcher to participants who 
needed clarity on any questions. 
On completion of the questionnaires, they were collected and coded. A register of 
these participants with their corresponding coding was opened and their details 
entered. 
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2.5 Intervention Phase (Phase 2) 
One month after Phase 1, all patients visiting the ARV clinic were comprehensively 
counselled by the pharmacists on all aspects of their medicines, medicine taking in 
terms of when to take it and how to take it, disease condition i.e. how HIV and AIDS 
is caused; what HIV and AIDS stands for; how it is transmitted; how it can be 
avoided, together with information on storage i.e. where it should be stored and at 
what temperatures it should be stored, side effects that could be experienced by 
patients such as fatigue, headaches, skin rashes, nausea and diarrhoea, peripheral 
neuropathy, nightmares etc. and the importance of adherence. The pharmacist further 
helped the patient to plan dose times, explain what to do if a dose was missed and 
suggest ways to remember to take medication and also how to manage side effects. 
This counselling session lasted about ten minutes for each patient. 
2.6 Post-Intervention Phase (Phase 3) 
After the counselling session those patients that participated in Phase I of the study 
were once again asked to consent to be part of Phase 3 of the study. 
The same questionnaire that was used in Phase 1 was again completed by the 
participants who gave consent to be part of this phase. In order to ensure 
confidentiality, the register of the participants was destroyed after the completion of 
Phase 3 of the study. 
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2.7 Data Analysis 
The data was captured and analyzed using SPSS version 15.0 (SPSS Inc., Chicago, 
Illinois, USA). Knowledge was scored allocating a score of 1 to each correct answer 
and then summing up the scores, and expressed as a percentage out of the total 
possible score with higher percentages indicating higher levels of knowledge. The 
changes in all factors between pre and post intervention were assessed statistically. 
Quantitative variables were compared between pre and post using paired t-tests or 
Wilcoxon signed ranks tests. Categorical variables were tested using McNemar's chi 
square test (Binary) or McNemar-Bowker test for ordinal variables. 
2.8 Ethics 
Ethical approval was obtained from the University of KwaZulu-Natal Research and 
Ethics Committee (ethics clearance number: FECHSC 002/07) and from the senior 
management of the study site and the provincial health department in KwaZulu-Natal. 
Anonymity of responses was maintained by requesting participants not to disclose 
their personal details on the questionnaires. 
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CHAPTER 3 
RESULTS AND ANALYSIS 
3.1 Response Rate 
200 persons consented to be part of Phase 1 of this study. Only 175 completed the 
second phase ofthe study resulting in a response rate of 87.5% 
3.2 Demographic profile of the participants 
The demographics of the participants are depicted in Table I 




Male 39 22.3% 
Female 136 77.7% 
AGE GROUP 
21-30 47 26.8% 
31-40 75 42.8% 
41-50 45 25.7% 
51-60 7 4% 
61-70 1 0.5% 
POST SCHOOL EDUCATION 
Yes 13 7.4% 
No 162 92.6% 
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The majority of the patients were female. Almost 70% of the participants were in the 
age-range of 21-40 years old. Majority of the participants did not have post school 
education. 
3.3 Knowledge of HIV and AIDS 
3.3.1 General HIVand AIDS knowledge 
Table II: General knowledge of HI V and AIDS (n=175) 
Question 
HIV is a bacteria which causes AIDS 
People with AIDS cannot fight sicknesses such as diarrhoea, TB and pneumonia 
The HIV virus attacks the heart and liver 
You can tell from a persons' appearance that they have the HIV virus 
A person has less chance of getting the HIV virus if they have one partner 
A person can get infected with the HIV virus if they have unprotected sex with 
someone who has HIV 
People who have sexually transmitted diseases (STD's) are least at risk of getting the 
HIV virus 
Not all babies whose mothers are HIV positive, are born with the virus 
Healthy food will cure HIV 
Smoking and drinking alcohol will strengthen the body 
Smoking and drinking alcohol will weaken the HIV virus 
Support groups cannot help people with HIV and AIDS deal with anger and 
loneliness 
Diarrhoea is when you pass two or more loose or watery stools a day 
When a person starts to cough, cough mixtures to stop the cough can be taken 
People with HIV and AIDS have problems with their skin, for example rash 




















Most of the participants (95.4%) did not know that HIV is a virus that causes AIDS in 
the pre intervention phase, but this decreased to 93.7% in the post intervention phase. 
The participants' knowledge of people who have sexually transmitted diseases are 
least at risk of getting HIV, healthy food will cure HIV and smoking and drinking 
alcohol will weaken the HIV, increased significantly from the pre-intervention phase 
to the post intervention phase. 
When asked if their antiretroviral medication was a complete cure, 87.4% said no 
whilst a small minority 10.3% said yes and 2.3% were unsure prior to the 
intervention. 
After the intervention, 88.6% said no, while 8.6% said yes and 2.9% did not know. 
3.3.2 Knowledge of modes of transmission 
Table III: Modes oftransmissioo (0=175) 
Modes of Transmission % Correct 
Pre post 
Sharing Needles with a person infected with HIV and AIDS 97.7% 99.4% 
Unprotected sexual contact with a person infected with HIV and AIDS 99.4% 100.0% 
Contact with blood 98.3% 98.3% 
Sharing toilet seats with a person infected with HIV and AIDS 93.1% 95.4% 
Using the same eating and drinking utensils of a person infected with HIV and 95.4% 
96.0% 
AIDS 
Kissing a person infected with HIV and AIDS who has sores in his or her mouth 84.0% 87.4% 
Touching a HIV patient 94.9% 94.9% 
Being bitten by a mosquito 68.6% 75.4% 
Sexual contact with a homosexual with an unknown HIV status 15.4% 15.4% 
Working with a person infected with HIV and AIDS 96.6% 96.0% 
Sexual contact with too many partners with an unknown HIV status 92.0% 97.1% 
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Knowledge on the modes of transmission either increased or remained unchanged. 
Majority of the participants (94.6%) did not know that sexual contact with a 
homosexual with an unknown HIV status can result in HIV. 
3.3.3 Knowledge of HIV prevention 
Table IV: Responses on HIV prevention (n=175) 
Prevention % Correct 
Pre post 
By abstaining from sex 93.7% 94.9% 
By using latex barriers (condoms) 97.7% 97.1% 
By preventing needle sharing 98.9% 98.3% 
By being faithful to one partner 97.1% 96.0% 
By not associating with HIV and AIDS patients 91.4% 92.6% 
The mean knowledge score Pre-Intervention was 82.1 % with a standard deviation of 
6.6% while after the intervention it had increased to 86.3% (SD 6.6%). 
Table V: Paired t-test for the comparison of mean knowledge score pre and post 
intervention 
Mean N Std. Deviation Std. Error Mean p value 
knowledge score Pre-Intervention 82.10 175 6.598 0.499 <0.001 
knowledge score Post-Intervention 86.35 175 6.628 0.501 
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3.4 Participants perceptions of mv and AIDS 
Table VI: Perceptions of HI V and AIDS (n=175) 
Perception % Correct 
Pre 
Sex with a virgin can cure HIV and AIDS 97.7% 
Sex with a child can cure HIV and AIDS 100.0% 
Traditional healers can cure HIV and AIDS 97.7% 






All but one participant pre intervention (n=174, 99.4%) reported that they ate a 
balanced healthy diet, and 100% reported eating a balanced healthy diet post 
intervention. Most of the participants (over 90%) stated that fruit; vegetables; dairy 
products; chicken; red meat and starches formed the main components of their diet. 
3.5 Counseling 
3.5.1 Adherence 
Twelve participants improved their adherence from pre to post intervention, whilst 4 
of the participants adherence worsened. Although this suggests an improvement trend, 
it could not be confirmed statistically. (p=O.077) 
3.5.2 Side efficts 
When asked if the side effects of the medication were explained to the participants, 
98.3% (n=l72) said yes whilst 1.7% (n=3) said no in the pre-intervention phase. This 
increased to 100% (n=175) in the post intervention phase. 
In terms of participants' understanding of medication and side effects, when side 
effects were experienced, 96% (n=168) said they would go to a doctor or clinic 
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immediately in the pre-intervention phase. This increased to 99.4% (n=174) post-
intervention. 
When asked what they would do if they vomited after taking their medication, 94.9% 
(n=166) stated that they would take their medication again if they vomited less than 
30 minutes after taking the medication, and at post intervention this improved to 
97.7% (n=171). 92% (n=161) said they would do nothing if they vomited more than 
30 minutes after taking their medication pre intervention while this improved to 96% 
post-intervention. 
Thus the intervention resulted in a slight improvement in medicine taking, none of 
which were statistically significant. 
3.5.3: Storage of antiretroviral medication 
Table VII: Storage of antiretroviral medication pre and post intervention (n=175) 
Pre-Intervention Post-Intervention 
% % 
Stavudine Cupboard 49.1% 51.4% 
Handbag 31.8% 32.9% 
Other 19.1% 15.6% 
Lamivudine Cupboard 49.7% 52.0% 
Handbag 31.4% 32.6% 
Other 18.9% 15.4% 
Nevirapine Cupboard 43.2% 47.2% 
Fridge .0% 2.8% 
Handbag 40.5% 44.4% 
Other 16.2% 5.6% 
Efavirenz Cupboard 52.5% 54.0% 
Handbag 28.8% 29.5% 
Other 18.7% 16.5% 
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In both phases, over 40% of all patients stored their medication in the cupboard. There 
were no significant differences in terms of storage of the antiretroviral medication in 
both pre and post intervention. 
3.5.4 Ways in which medication are taken 
Table VIII: Ways in which antiretroviral medication are taken (n=175) 
Pre Post 
% % 
Stavudine with food 62.4% 70.5% 
without food 14.5% 11.0% 
empty stomach 22.0% 18.5% 
fatty meal .6% .0% 
any time when I remember .6% .0% 
Lamivudine with food 62.3% 70.3% 
without food 14.9% 11.4% 
empty stomach 21.7% 18.3% 
fatty meal .6% .0% 
any time when 1 remember .6% .0% 
Nevirapine with food 57.9% 69.4% 
without food 13.2% 13.9% 
empty stomach 28.9% 16.7% 
Efavirenz with food 63.5% 70.5% 
without food 15.3% 10.8% 
empty stomach 19.7% 18.7% 
fatty meal .7% .0% 
any time when I remember .7% .0% 
Table VIII shows that the frequency of initially reported taking medication with a 
fatty meal or any time they remember was decreased after the intervention to O. The 
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majority of the patients took their medication either with or without food at both 




The respondents knowledge on HIV and AIDS (p<O.OOl) and on medicine taking and 
storage (p<O.05) had increased significantly after the intervention of the pharmacist 
which suggested that the pharmacist did make a positive impact on the knowledge of 
the HIV infected patients who attended the public sector facility where the study was 
carried out. 
In terms of the specific questions asked on general knowledge, most of the 
participants knew about the disease with the exception of the question relating to HIV 
being a bacteria that causes AIDS, where a very small percentage knew the correct 
answer. 
One possible reason could be that the participants may not have known that there is a 
difference between a bacteria and a virus as over 92% of them did not have post-
school education. 
Despite the pharmacist counselling the patients, the second possible reason could be 
that those respondents still believed that HIV (irrespective of whether it is a bacteria 
or a virus) does not cause AIDS. This belief could have been influenced by the 
dissident view shared by the previous South African President, Mr Thabo Mbeki, 
where he stated that HIV was not responsible for AIDS.58•59 
With regard to sexually transmitted infections being a risk to contract HIV, just over a 
third of the respondents had answered correctly however after the intervention about 
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two thirds of the respondents showed a greater knowledge towards sexually 
transmitted diseases and HIV infection. This finding is also supported by a study done 
in Ghana where it was found that pharmacists played a crucial role in the effective 
management of sexually transmitted infections.60 
Another study done amongst high school students in Kathmandu Valley, Nepal, found 
that pre-education knowledge of sexually transmitted infections was quite low 
(41.7%) as compared to post-education knowledge which increased to 87.2%.61 
Smoking and drinking alcohol seemed to be perceived by some of the respondents as 
a means of weakening the virus as only 68% of the respondents answered this 
question correctly before the intervention of the pharmacist. Even though this number 
greatly increased after the intervention, a small percentage of 6.9% still believed that 
smoking and drinking alcohol does have an effect on the virus. This could possibly be 
one of the reasons why smoking and alcohol consumption are so common amongst 
HIV infected individuals as shown by some studies.62 Other studies have shown that 
smoking and alcohol consumption amongst HIV positive individuals is high, due to 
the stress caused by HIV status disclosure. Also many patients believed that stopping 
smoking would not improve their health.63 
In this study a small percentage of the respondents, both in the pre-intervention 
(12.6%) and post-intervention (11.4%) phases, felt that AIDS could be cured which 
correlated to a study done in Malaysia amongst young Malaysian adults where it was 
found that 18.1 % believed that there was a cure for AIDS.64 
A large majority of the study population knew how HIV was transmitted with a 
further increase in the numbers knowing the different modes of transmission after the 
pharmacist intervention. However the percentage that responded to the question on 
whether sexual contact with a homosexual with an unknown HIV status can cause 
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AIDS remained the same in both the pre and post intervention phases even though the 
pharmacist counselled them. A possible reason could be that the terminology 
'homosexual' had been used and not the common terminology 'gay', thus leading to 
respondents being confused or not understanding the question but too afraid to ask. 
Possible reasons could be that some patients may feel embarrassed to ask questions. 
Studies have shown that patients are afraid to ask questions or request explanation of 
terms for fear of being ridiculed, fear of the illness and treatment or fear of the doctor, 
in this case it could be the researcher.65 
Almost a third of the respondents believed that being bitten by a mosquito could 
transmit the virus, however of concern is that even after the intervention, a quarter of 
the respondents still maintained this belief. The belief that mosquitoes are vectors for 
HIV is a quite common misconception that has been shown in other studies as well.66 
A further concern was that even though the respondents were counselled by the 
pharmacist and there was a positive outcome, a small percentage of respondents still 
retained their own beliefs. With the exception of whether having unprotected sex can 
transmit the virus, the other responses in the post intervention phase did not give a 
100% positive response to the questions. Of concern were questions on transmission 
(viz. via contact with blood, HIV infected persons with sores in mouth being kissed, 
sexual contact with too many partners of unknown status could lead to risky 
behaviours) which if respondents do not accept as means of possible modes of 
transmission could further lead to the spread of the virus. Therefore more education 
on the different modes of transmission is essential in order to prevent further 
transmission thereby containing the epidemic. 
Over 91 % of the respondents were familiar with HIV prevention methods as they 
answered correctly to the questions given. However a small percentage still did not 
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change views or beliefs even after the intervention in that they still maintained that 
abstaining from sex, using condoms, being faithful to one partner etc. would not 
contribute as mv prevention methods. The finding relating to condom use correlates 
to another study where it was found that only 79.5% knew that HIV could be 
prevented by using condoms.64 
Even though 12 participants improved adherence from pre to post intervention in this 
study and although it was not statistically significant, there was an improvement with 
the intervention of the pharmacist. This can be likened to a US based study where it 
was shown that few non-compliant patients obtained an undetectable viral load prior 
to the pharmacists' intervention. However a significantly higher proportion of patients 
achieved an undetectable viral load after attending a pharmacist counselling clinic. In 
treatment experienced patients, the incorporation of a pharmacist in the HIV care team 
had a significant impact on patient outcomes.67 
In terms of side effect knowledge, the pharmacist intervention resulted in an improved 
response from the pre to the post intervention phases. 
Pharmacists played a positive role in the way patients took their medication with 
regard to food in that most patients would avoid taking their medication with a high 
fatty meal after the intervention and took their medication correctly either with or 
without food. This is important since food can affect the absorption, metabolism, 
distribution and excretion of antiretroviral medication. Important interactions include 
efavirenz with a high fatty meal which should be avoided due to an increased drug 
absorption.51 
Some of the respondents chose the bedroom, drawers in bedroom, drawer in dressing 
table, headboard, in a box, in a bag, in shoe box, in underwear drawer, on top of 
wardrobe and on shelves in bedroom as places of storage for their antiretroviral 
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medication. This proved to be interesting since patients seemed to be hiding their 
medication. This could have been due to the patients not wanting anyone to know 
their HIV status and also because HIV is associated with stigma and discrimination, 
as these individuals, if found out to be HIV positive, could face rejection by their 
families and communities.z6 AIDS related stigma and discrimination can also directly 
hamper the effectiveness of AIDS responses. Stigma and discrimination can directly 
affect the likelihood of protective behaviours.68 
Most of the participants stored their medication either in their handbags or in the 
cupboard. This could have been done out of convenience and also because of 
accessibility. Therefore no amount of counselling could have changed this behaviour. 
Only a small percentage of respondents (2.8%) wanted to store their medication in the 
fridge even after the intervention of the pharmacist. A possible reason could be that 
they did not have a fridge and those who indicated after the intervention that they 
stored their medicines in a fridge could have acquired one or found a fridge where 
they could store their medicines after knowing the importance of storing ARV 
medications in the fridge. 
In terms of perceptions of HIV and AIDS, when asked if sex with a child can cure 
HIV and AIDS, 100% of the participants answered correctly however after the 
intervention l. 7% of the participants answered incorrectly. A question similar to this 
that asks if having sex with a virgin can cause AIDS, resulted in 2.3% of the 
participants answering it incorrectly in both the pre and post intervention phases even 
after the pharmacist intervention. This finding is consistent with studies where it has 
been shown that people believe the myth that having sex with a virgin could cure 
AIDS. These people would choose a child with the belief that the child is more likely 
to be a virgin.69 
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Another study done in Lesotho, had shown that some people believe that having sex 
with a virgin can cure HIV infection and they also feel that having sex with a child is 
similar to having sex with a virgin.7o 
Limitations 
This study was limited to patients who were willing to participate in the study. The 
sample size was relatively small and confined to one hospital. Secondly, the reliability 
and validity of the participants' self reporting was unknown. 
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CHAPTERS 
CONCLUSION and RECOMMENDATIONS 
CONCLUSION 
This study shows that a pharmacist led intervention can lead to a significant 
improvement in the knowledge of HIV and AIDS patients regarding the HIV disease, 
its mode of transmission, prevention methods and antiretroviral medication use, 
storage and also adherence to medication. Pharmacists play a crucial role in 
distributing AIDS-related information to the public and promoting the understanding 
ofHIV and AIDS. 
RECOMMENDATIONS 
• Pharmacists whether in the public or private healthcare sector should become 
more involved in the management of HI V infected patients. 
• Pharmacists should playa pivotal role in the dissemination of HIV and AIDS 
information. 
• The data from this research study could be a useful guide in the development 
of campaigns or programmes designed to convey accurate information about 
HIV and AIDS in terms of knowledge and adherence. 
• Interventions such as patient education, counselling, health promotion, 
reminders and provision of resources should be employed to improve 
adherence to HAART. 
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• Another intervention study should be done with a larger sample size and a 
longer interval between the pre and post intervention with similar variables 
from this study 
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Patient questionnaire (English) 







3. ARE YOU SOUTH AFRICAN OF 
African origin Indian origin Coloured origin White origin Non South African 
D D D D D 
4. WHAT IS YOUR HIGHEST GRADE OF FORMAL EDUCATION 
Grade -----
4a. IF YOU HAVE COMPLETED GRADE 12, DO YOU HAVE ANY POST 
SCHOOL EDUCATION 
Yes D No D 
4b. IF YES, PLEASE SPECIFY 
5. HOW LONG HAVE YOU BEEN TAKING THE MEDICINES FOR 
_______ Months ________ Years 





Kaletra TM(LopinavirlRitonavir) 0 
Efavirenz(EFV, EFZ, STOCRIN™Q 
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7. HOW MANY PILLS DO YOU TAKE PER DAY FOR THE HIV INFECTION 
8. HOW MANY TIMES A DAY DO YOU TAKE THE MEDICATION AND AT 
WHAT TIMES DO YOU DO THIS 
Medication Number of Timeffimes Don't Don't Other times 
times know, know, 
anytime anytime 
when it is when 
convenient convenient. 
day and Only during 















9. HAVE YOU EVER MISSED TAKING MEDICATION ON ANY DAY SINCE 
STARTING THE ARV MEDICATION 
Yes 0 NoO 
9a. IF YES, HOW OFTEN DOES THIS HAPPEN 
Once a day Once a week Twice a week other-specify 
o 0 0 0 
9b. SINCE WHEN HAS THIS HAPPENED 
In the last month In the past 2 months In the last 6 months 
D D D 
In the last year 
D 
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9c. INDICATE THE REASON FOR NOT TAKING THE MEDICATION AND 
ALSO INDICATE HOW OFTEN THIS WAS THE REASON FOR YOU NOT 
TAKING THE MEDICATION 
Never Rarely Sometimes Most of the Always 
time 
Was away from home 
Forgot to take pills 
Had too many pills to take 
Had too many side effects 
Did not want anyone to 
know my HIV status 
Had problems taking pills 
at specific times of day 
Had other illnesses as well 
There are too many 
directions to take meds. 
Ran out of medication 
Shared medicines, did not 
have enough for myself 
Was busy with other 
things 
Found difficulty in 
swallowing medication 
Don't know why 
medication is being; taken 
Have to take medication 
too many times a day 
I was in school 
Other 
10. DO YOU HAVE SOMEONE TO REMIND YOU TO TAKE MEDICATION 
Y es-always Yes-sometimes No 
D D D 
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11. HOW DO YOU STORE YOUR MEDICATION(tick all that apply) 




















12, HOW DO YOU TAKE THE FOLLOWING MEDICATION(only tick under the 
d' f th tI t k' ) me lca tOn at you are curren ly a mg, 


















13 DO YOU EXPERIENCE ANY OF THE FOLLOWING SIDE EFFECTS: 














Problems sleeping (insomnia) 
Enlargement of breasts 
(Gynaecomastia) 
Hyperlactaemia 
Nausea, vomiting, abdominal 
pain, fatigue, weight loss 
(lactic acidosis) 
Other 
13a. WHAT DO YOU DO WHEN THESE SIDE EFFECTS ARE EXPERIENCED 
Stop the medication completely D 
Go to a doctor/clinic as soon as possible D 
Stop medication and then start again D 
Don't know D 
13b.HA VE THE SIDE EFFECTS OF THE MEDICATION BEEN EXPLAINED TO 
YOU BEFORE YOU STARTED TAKING THE MEDICATION 
Yes D No D 
14a. WHAT DO YOU DO IF YOU VOMIT LESS THAN 30 MINUTES AFTER 
TAKING THE MEDICATION 
Do nothing Take pills again Don't know 
D D D 
14b.WHAT DO YOU DO IF YOU VOMIT MORE THAN 30 MINUTES AFTER 
TAKING THE MEDICATION 
Do nothing Take pills again Don't know 
D D D 
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15. DO YOU FEEL THAT THE MEDICATION ARE WORKING FOR YOU 
Yes D NoD 
lSa.lF YES, HOW DO YOU KNOW THAT THEY ARE WORKING 
I feel better D 
I can go to work D 
I am not tired D 
I do not feel sick D 
Other D 
ISb.IF NO, HOW DO YOU KNOW THAT THEY ARE NOT WORKING 
I still feel sick D 
I still cannot go to work D 
I feel tired all the time D 
Other D 
16. DO YOU COME EVERY MONTH TO COLLECT THE MEDICATION 
Yes D NoD 
16a.IF NO, WHAT IS THE REASON FOR NOT COMING TO COLLECT THE 
MEDICATION EVERY MONTH 
Clinic is too far 
No transport 
Unwell 




17. WITH REGARD TO THE FOLLOWING STATEMENTS, PLEASE TICK IF 
TRUEIFALSE 
True False 
*HIV is a bacteria which causes AIDS D D 
*People with AIDS cannot fight 
D D sicknesses such as diarrhoea, TB and 
pneumonia 
*The HIV virus attacks the heart and liver D D 
*y ou can tell from a persons' appearance D D that they have the HIV virus 
* A person has less chance of getting the D D 
HIV virus if they have one partner 
* A person can get infected with the HIV D D virus if they have unprotected sex with 
someone who has HIV 
*People who have sexually transmitted 
diseases (STD's), are least at risk of D D 
getting the HIV virus 
*Not all babies whose mothers are HIV 
positive, are born with the virus D D 
*Healthy food will cure HIV D D 
*Smoking and drinking alcohol will D D strengthen the body 
*Smoking and drinking alcohol will D D 
weaken the HIV virus 
*Support groups cannot help people D D with HIV and AIDS deal with anger 
and loneliness 
*Diarrhoea is when you pass two or D D more loose or watery stools a day 
*When a person starts to cough, cough 
D D mixtures to stop the cough can be taken 
*People with HIV and AIDS have problems 
with their skin, example rash 
D D 
* A person can get re-infected with HIV D D 
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18. THE CAUSE/S OF HIV AND AIDS IS/ARE 
Yes No Don't know 
*Sharing needles with a person 
D D D infected with HIV and AIDS 
*Unprotected sexual contact with 
a person infected with HIV and D D D 
AIDS 
*Contact with blood D D D 
*Sharing toilet seats with a person D D D 
infected with HIV and AIDS 
*Using the same eating and drinking D D D utensils of a person infected with HIV 
and AIDS 
*Kissing a person infected with HIV D D D 
and AIDS who has sores in hislher 
mouth 
*Touching a HIV patient D D D 
*Being bitten by a mosquito D D D 
*Sexual contact with a homosexual D D D 
*Working with a person infected with D D D HIVandAIDS 
*Sexual contact with too many partners D D D 
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19. HIV AND AIDS CAN BE PREVENTED 
Yes No Don't know 
*By abstaining from sex D D D 
*By using latex barriers D D D 
(condoms) 
*By preventing needle D D D 
sharing 
*By being faithful to one D D D partner 
*By not associating with D D D 
HIV and AIDS patients 
20. DO YOU THINK THAT 
Yes No Don't know 
*Sex with a virgin can cure D D D 
HIVandAIDS 
*Sex with a child can cure D D D HIVand AIDS 
*Traditional healers can cure 
D D D HIVand AIDS 
*If a person is too thing, he/she D D D 
has HIV AND AIDS 
21. DO YOU THINK THAT THE ARV MEDICATION IS A COMPLETE CURE 
FOR HIV AND AIDS 
Yes No Don't know 
D D D 
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22. DO YOU EAT A BALANCED, HEALTHY DIET? 
Yes No 
D D 




Patient questionnaire (Zulu) 
IMIBUZO YEZIGULI 













4. IZINGA LAKHO ELIPHEZULU LEZEMFUNDO 
Ungowoku Hamba 
D 
4a.UMA UWUHOTHULILE UMATIKULETSHENI,INGABE WAKWAZI 
UKUQHUBAKA. 
YeboO ChaO 
4b.UMU KUWU YEBO, SICELA WENABE 
5. LEMITHI USUYITHATHE ISIKHATI ESINGAKANANI: 
_____ Izinyanga eziwu _____ Iminyaka ewu 





Kaletra TM(LopinavirlRitonavir) 0 
Efavirenz(EFV, EFZ, STOCRIN TMp 
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7. MANGAKI AMAPHILISI OWATHA THA YO NGELANGA OWATHA TELO 
IGCIW ANE LESANDULELA NCULAZI 
8. UWATHATHA IZIKHATHI EZINGAKI AMAPHILISI FUTHI NGAZIPHI 
IZIKHATHI 
Umuthi Izikhathi Nga siphi Angazilnoma AngazilNoma Nsezinye, 




















9. SELOKHU WAQALA UKUTHATHA IMITHI YAKHO,USUKE 
W AKHOHL WA NJE UKUYITHATHA 
YeboO ChaO 
9a.UMA KUWU YEBO SEKWENZEKE IZIKHATHI EZINGAKI 
Kanye osukwini Kanye evikini Kabili evikini Okunye 
o 0 0 o 
9b.KWENZEKE NINI LOKHU 
izikhathi 
Ngenyanga eyedlule Ezinyangeni ezinbili ezedlule Ezinyangeni eziyithupha ezedlule 




9c. A WUCHAZE 1MB ANGELA YOKUNGA WATHA THI AMAPHILISI FUTHI 
UKHAZE UKUTHI KWENZEKE IZIKHATHI EZINGAKI. 
Awukaze Akuva Kuyenzeka Izikhathi Njalo 























ngingenawo awami anele 
Ngangibambekile 











10. KUKHONA NJE UMUNTU OKUKHUMBUZA YO UKUTHI UTHATHE 
IMITHI 
Yebo-njalo Yebo-kuyenzeka ngesinye isikhati Cha 
D D D 
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11. IMITHI Y AKHO UYIGANU KANJANI (Tshengisa ngamake) 























12. LAMITHI ELANDELAYO UYITHATHA KANJANI (faka umaki ngaphansi 
kwemithi oyithathayo ku )hela) 
















13. INGABA IMITHI IY AYE IKWENZE UZIZW A SENGATHI UNOKUNYE 
KWALO KHI OKULANDELA YO 
Yebo Isikhathi okwenzeka 























13a. WENZE NGANI UMA LAZIZINTO EZINGAPHAZULU OZISHILO 
ZIKUHLASELA 
Ngiyayiyeka imithi ngingabe ngisayithata nhlobo 0 
Ngiya kudokotelaleclinic ngokushesha 0 
Ngiyayiyeku la se ngiphinda ngiyithatha futhi 0 
Angazi 0 
13b.INGABE W ACHAZELA NGALEZI EZINTO EZIMBI EZENZIW A 
YILEMITHI NGESIKHA THI UQALA UKUTHA THA IMITHI 
YeboD ChaO 
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14a.WENZENJANI UMA UBUYISILE EMIZUZWINI ENGAPHANSI KWEWU 30 
EMV A KOKUTHATHA IMITHI 
Angenzi lutho Ngikhatha amanye Argji 
o 0 
14b. WENZENJANI UMA UBUYISILE EMIZUZWINI EWU 30 EMW A 
KOKUTHA THA AMAPHILISI 
Angenzi lutho Ngikhatha amanye Angazi 
DOD 
15. UCABANGA UKUTHI LEMITHI IY AKUSEBENZELA 
YeboO ChaD 
15a.UMA KUWU YEBO, WAZIKANJANI UKUTHI AYASEBENZA 
Ngizizwa ngingcono 0 
Sengiyakwazi nokuya emsebenzini 0 
Angisakhathali 0 
Angizizwa ngigula D 
Okunye D 
15b.UMU KUWU CHA, W AZI KANJANI ULUTHO A WASEBENZI 
Ngizizwa ngesagula 0 
Arigikakwazi ukuya emsenenzini D 
Ngizizwa ngikhathele ngasonse isikhathiD 
Okunye o 
16.UZA NGAZO ZONKE IZINYNGAUKULANDA IMITHI Y AKHO 
Yebo D Cha D 
16a.UMA KUWU IYIPHI IMBANGLA EKWENZA UNGAKWAZI UKULONDA 
IMITHI Y AKHO ZINY ANGA ZONKE 
Iklinikhi ikude kakhulu 
Anginayo into yokuhamba 
Uyagula 




17.MAYELANA NALEZIZITAIMENDE, FAKA UMAKI USHO UKUTHI 
IQUNISO NOMA 
Qiniso Amanga 
*i-HlV iyigciwane elidala AIDS(ingculaza) D D 
(isandulela ngculaza) 
* Abantu abane AIDS (ingculaza) abakwazi D D ukulwa nezifo ezifana nesifo sohhvoo, nesifo 
sesifuba (TB), isifo sama khaza esihlasela 
amaphaphu 
*Isandulela sengculazi sihlasela inhliziyo kanye D D 
nesibindi 
*Uyakwazi ukubona ngendlela abukeka ngayo D D ununtu ukuthi une-sandulela senglulaza 
*Umuntu othandawa nomuntu oyedwa unama D D 
thuba amangane ukuthu abe-sandulela ingculaza 
*Umuntu angiyithola isandulela ngculaza uma eya D D 
ocansini akazi vikelanga nomuntu onesandulela 
sengulazi 
* Abantu abanezifo zocansi ezesulelanayo 
basemathubeni amancane ukuthi bathole isifo 
sesandulela ngculaza D D 
* Akusibo bonke omama abanesifo sesandulela 
ngculaza ukuthi izingane zabo zizalwa nalo D D 
19c1wane 
*Ukudla okunempilo kuyayilapha incgulaza D D 
*Ukubhema kanye nokuphuza utshwala kuwunika D D amandla umzim ba 
*Ukubhema kanye nokuphuza utshwala kuwenza D D 
cibethaka isandulela ngculaza 
*Itimba labantu labalekelelayo atibasizi abantu D D 
abenegculaza kanye nesesandulela ngculazi 
ukuze bakwazi ukuthi bamelane nokucasuka 
nomzwangedwa 
*Isifo sohhvoo senzaka uma-ukhishwa isisu D D esihlabulukile esikukhipaya 
*Uma umuntu eseqala ukukohlela, kumele 
D D aphuze umuthi wokukohlela 
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* Abantu abanengculaza nesandulela ngculaza D D 
Babanenkinga nezikhumba, isibonga irash 
*Umuntu angaphinde ayithole ingculaza D D 
18.IMBANGELA YOKUTHELA IGCIW ANE LE HIV ILELILEZI 
EZILANLELA YO 
Yebo Cha Angazi 
*Ukusebensisa izinaliti ezidowa 
nomuntu onegawane Ie HIV nengculaza D D D 
ngaphandle kokuviketa 
*Ukulala nomunu onegciwane Ie mv D D D nengculaza 
*Ukuhlangana kwegazi D D D 
*Ukuhlala esihlalweni zendlu D D D 
yoingasese ebesihlale umuntu 
onegcwane Ie HIV nengculaza 
*Ukusebenziza izinto ezizodwa D D D zokudla nomuntu onegciwane 
Ie HIV nengculaza 
*Ukuqabulana nomuntu onegawane D D D Ie HIV nengculazu nezilonde emlonyeni 
*Ukuthinta umuntu onegawane Ie HIV D D D 
*Ukulunywa umoskito 0 0 0 
*Ukulala nomuntu oyinkonkoni 0 0 0 
*Ukusebenza nomuntu onegcwane Ie HIV 0 0 0 nengewu 
*Ukulala nabantu abaningi ozwana D D D 
nabo 
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19.1GCIW ANE LE HIV NENGCULAZA LINGA VlKEL W A 
Yebo Cha Angazi 
*Ngokuthi ona kwi-sex/ D D D 
ukulalana 
*Ngokusebenzisa ama- D D D 
khondomu 
*Ngokuvimbela 
ukusebenzisa inilithi eyodwa/ 
D D D 
ezizokwa 
*Ukuziphatha kahle kumuntu D D D wakho oyedwa 
*N gokungahlale/ngokungazi 
andakanyinabantu D D D 
abasegabwane Ie HIV ne ingculazi 
20.INGABE UCABONGO UKUTHI? 
Yebo Cha Angazi 









0 D 0 zingalelapha 19ciwane 
lesandulela ngculazi nengulazi 
*Uma umuntu ehlile emzinbeni D 0 0 
(owondile) kusho ukuthi 
unesandulela ngculazi nengculazi 
21.UCANGA UKUTHI IMISHANGUZA AMA ARV A YILAPHAIPHELE 
IGCHLAZI 
Yebo Cha Angazi 
D D D 
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22.NGABE UDLA UKUDLA OKUNEMPILO? 
Yebo Cha o 0 







Re: Research Project: Informed Consent 
I am currently doing a study to determine if you have any problems with your 
antiretroviral medication in terms of how you take it and whether you take it regularly 
or if not, why not. The study involves doing research. There are no right or wrong 
answers. The information you give will help me find better ways to help you. It is 
voluntary to answer these questions and the answers you give are strictly confidential. 
In this research, I will also be looking at your prescriptions or history profile to see if 
your medication have been taken regularly and also if you are adhering to treatment. 
All your information, whether your name, diagnosis, or treatment will be confidential. 
Later, I will need to contact you again to re-question you in order to see if your 
adherence to treatment is improved or not. 
I thank you very much for your help. 
~numzane~osazana 
Ngenza ucwaningo ukuze ngithole ukuthi unayo yini inkinga mayelana nendlela 
yokuthatha imishanguzo yegciwane lesandulela ngculazi (phecelezi, ama-
antiretrovirals). Ulwazi ozonginikeza lona luzongisiza ukuthi ngikwazi ukuthola 
indlela egcono yokukusiza. Awuphoqekile ukuphendula le- mibuzo futhi izimpendulo 
zakho zizogcinwa ziyimfihlo phakathi kwami nawe. Kulolu-cwaningo, ngizobheka 
uhlobo lwemishanguzo oluseenzisayo noma umlando wokuthatha lemishanguzo 
ukuze ngibone ukuthi ikusizile yini nokuthi ubuyithatha ngendlela efanele yini. Yonke 
imininingwane yakho, igama lakho, isifo esikugulisayo noma imishanguzo 
oyithathayo izogcinwa iyimfihlo phakathi kwani nawe. Sekunyothi ngemuve nje 
kwazinsuku waqala ukuphuza imishanguzo ngiphinde ngixhumane nawe ngocingo 






Patient Consent Form: 
I, (name) , hereby consent to participate in the study. The 
study has been explained to me in a language that I understand and I do not have any 
objections to having my information given to the researcher. I understand all 
information will be confidential and I will remain anonymous and that there will be 
no way in which information provided by me will be identified with me. I am also 
aware that if at any stage I withdraw from the study there will be no penalties for my 
action and that I could withdraw from the study ifl choose not to continue. 
Signed: ________ _ 
Dated: ---------
Mina (igama) , ngiyavuma ukuthi ngizobamba iqhaza 
kulesisifundo. Lesisifundo ngiye ngachazelwa ngaso ngolimi lwami engiluqondayo 
futhi anginazo izizathu zokuphikisana nokunikeza ulwazi lwami umcwaningi. 
Ngiyaqonda ukuthi lonke ulwazi luzoba yimfihlo. Futhi ngiyakwazi ukuthi uma 
kwenzeka ngihoxa kulolu cwaningo ngeke ngihlawuliswe ngesenzo sami futhi uma 
ngiqoka ukuthi ngingaqhubeki. 
Sayina: ________ _ 
Usunu: ---------
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